Along with those sleep benefits may come attendant improvements in energy, mood, cognitive function, and stress
Clinical Evidence for Dual-Peptide Weight Loss Therapy Published data on GLP-1 monotherapy shows average weight loss of 1522% over 68 weeks in phase 3 trials, with sustained improvements in waist circumference and cardiometabolic markers
What people report: Nausea that lasts for hours, not just while drinking Vomiting that feels more intense than typical hangovers Stomach pain or cramping Feeling full or bloated even after small amounts of alcohol One patient on a Mounjaro forum described having two glasses of wine at dinner and spending the next four hours feeling like I had food poisoning. Another said even a single beer made them feel sick for an entire day
Quick Answer: Semaglutide has minimal direct drug interactions but may increase hypoglycemia risk when combined with insulin or sulfonylureas, and oral semaglutide can affect absorption of medications like levothyroxine
However, comprehensive long-term human safety data does not exist
Thats far more than tirzepatides 13.4% to 15.7% reductions among people with T2D in SURMOUNT-2 and significantly more than semaglutides (Novo Nordisk Wegovy) 10.9% to 14.9% in previous trials
